Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Sny save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $42.19 -0.14% -0.14% 530K
|
|
| O: 0.0%
H: 2.86%
C: 0.13%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
nanobody fda positive ema program
Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC
Published: 2024-01-09 (Crawled : 22:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
drug companies achondroplasia positive treatment key therapeutics growth market
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
Published: 2023-12-15 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
first positive treatment ema africa
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive cancer growth study market
Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda
Published: 2023-12-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: -0.62%
H: 1.01%
C: 1.01%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
CPRX | $15.12 -1.43% -1.46% 7.4M
|
Health Technology
|
| O: -0.37%
H: 5.49%
C: 5.49%
companies positive growth study market
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published: 2023-12-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
positive ongoing collaboration study
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
dupixent positive copd results sanofi
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Generalized Anxiety Disorder Treatment Market to Showcase Positive Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Players - MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics
Published: 2023-10-30 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: -3.51%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.67%
H: 3.16%
C: 2.75%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.61%
H: 0.0%
C: 0.0%
positive treatment growth market
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
disease alzheimer’s positive results
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 15:30) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -2.24%
H: 7.12%
C: 4.11%
bnt211 candidate congress tumors positive update cell car-t therapy
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
Published: 2023-10-11 (Crawled : 14:00) - globenewswire.com
MLTX | $42.19 -0.14% -0.14% 530K
|
|
| O: 1.63%
H: 1.95%
C: -8.55%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
nanobody congress positive trial
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Published: 2023-10-04 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.48%
H: 0.2%
C: -0.33%
rna-1083 covid-19 vaccine positive influenza
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.15%
H: 1.32%
C: -0.02%
positive treat risk topline hypertension cardiovascular results study
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
Published: 2023-08-30 (Crawled : 14:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
covid-19 chmp vaccine positive
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.